← Back to guidelines
Cardiology1 paper

African histoplasmosis

Last edited: 6 h ago

Overview

African histoplasmosis, caused by Histoplasma capsulatum var. africanus, primarily affects immunocompromised individuals and those residing in endemic regions of Africa, presenting with varied clinical manifestations including pulmonary and disseminated disease 1.

Diagnosis

  • Clinical history of exposure to endemic areas
  • Radiographic findings suggestive of pulmonary involvement (e.g., nodular opacities, infiltrates)
  • Microbiological confirmation: sputum culture, histopathology with PAS staining 1
  • Serological tests (IgM/IgG antibodies) can be supportive but not definitive 1
  • Management

  • First-line treatment: Amphotericin B (initial dose typically 0.5-1 mg/kg/day) for severe or disseminated cases 1
  • Adjunctive therapy: Fluconazole (loading dose 800 mg, then 400 mg daily) for maintenance therapy in immunocompromised patients 1
  • Supportive care including hydration, nutritional support, and management of complications 1
  • Special Populations

  • Immunocompromised individuals: Higher risk of disseminated disease; require aggressive antifungal therapy 1
  • Urban vs Rural: No specific differentiation noted in the provided abstracts; management principles apply broadly 1
  • Key Recommendations

  • Initiate empirical antifungal therapy in immunocompromised patients with suspected African histoplasmosis before definitive diagnosis 1 (Evidence: Moderate)
  • Use Amphotericin B for severe or disseminated cases, transitioning to Fluconazole for maintenance therapy 1 (Evidence: Moderate)
  • Monitor and manage comorbidities such as malnutrition and alcohol-related disorders, which may complicate recovery 1 (Evidence: Expert opinion)
  • References

    1 Seftel HC. Diseases in urban and rural Black populations. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1977. link

    Original source

    1. [1]
      Diseases in urban and rural Black populations.Seftel HC South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (1977)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Pricing·Privacy & Terms·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG